Company:  VICAL INC (VICL)
Form Type:  10-Q
Filing Date:  11/7/2013 
CIK:  0000819050 
Address:  10390 PACIFIC CENTER COURT
.
 
City, State, Zip:  SAN DIEGO, California 92121-4340 
Telephone:  858-646-1100 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.40  
Change: 
0.00 (0.00%)  
Trade Time: 
Aug 17  
Market Cap: 
$27.36M
Trade VICL now with 

© 2017  
Description of Business
We research and develop biopharmaceutical products, including those based on our patented DNA delivery technologies, for the prevention and treatment of serious or life-threatening diseases. We currently have three active, independent or partnered, development programs in the area of infectious disease comprised of: * An ongoing Phase 3 trial of ASP0113 for prevention of cytomegalovirus, or CMV, reactivation in hematopoietic stem cell transplant, or HCT, recipients in collaboration with Astellas Pharma Inc., or Astellas. Astellas has completed enrollment in the Phase 3 clinical trial and expects top-line data to be available in the first quarter of 2018. * An ongoing Phase 2 trial of VCL-HB01, our Vaxfectin®-formulated therapeutic DNA vaccine for reduction of lesion recurrences caused by herpes simplex virus type 2, or HSV-2, infection.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        NOTES TO FINANCIAL STATEMENTS
          BALANCE SHEET
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 6. EXHIBITS
    SIGNATURE
  EXHIBIT 31.1
    CERTIFICATION
  EXHIBIT 32.1
    CERTIFICATION PURSUANT TO